First-generation tokenization limited the efficacy of clinical trial data; but enhanced real-world data points can transform patient outcomes. Learn more: [ Ссылка ]
For years, life science companies and organizations that support them have worked to overcome differences between efficacy results from clinical trials and real-world effectiveness. In today’s world of big data, so much information is at the fingertips of this industry. However, the lack of connectivity in de-identified data sets and the lack of precision in first-generation tokenization methods limit the utility of that information. What technology solutions is your organization considering or using to take real-world data and de-identified patient data to the next level?
Join experts from LexisNexis® Risk Solutions to:
+ Understand how to gain more precision and better insight into the entire patient experience
+ Unlock how SDoH and other sources of data collected outside of the clinical setting impact the patient
+ Uncover how your organization can benefit from access to enhanced real-world data points
A wealth of data can be extracted from vast sources of public records and proprietary data sources, but more data isn’t always better. Combining the right, clinically validated data points can transform your business and the outcomes you are working to improve.
